InsiderSignal.AI

InsiderSignal.ai

MLYS - Mineralys Therapeutics, Inc.

Insider Sale by Rodman David Malcom (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Rodman David Malcom, serving as Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 20,406 shares at $26.61 per share, for a total transaction value of $542,973.00. Following this transaction, Rodman David Malcom now holds 76,140 shares of MLYS.

This sale represents a 21.00% decrease in Rodman David Malcom's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, March 12, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 16, 2026, 4 days after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Rodman David Malcom

Chief Medical Officer

Rodman David Malcom is the Chief Medical Officer of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and chronic kidney diseases, headquartered in Radnor, Pennsylvania.[[2]](https://www.marketbeat.com/instant-alerts/mineralys-therapeutics-nasdaqmlys-insider-sells-20516736-in-stock-2026-01-13/)[[8]](https://www.streetinsider.com/SEC+Filings/Form+144+Mineralys+Therapeutics,+Filed+by:+Rodman+David+Malcom/25844211.html) In this role, he has been actively involved in the company's operations, as evidenced by multiple insider stock transactions, including selling 262,752 shares for over $9 million across three transactions in early January 2026 at average prices ranging from $34.83 to $35.87 per share, retaining 61,804 shares afterward.[[1]](https://longbridge.com/en/news/271714091)[[2]](https://www.marketbeat.com/instant-alerts/mineralys-therapeutics-nasdaqmlys-insider-sells-20516736-in-stock-2026-01-13/) Additional sales occurred on January 12, 2026 (6,348 shares at $32.32), January 9 (2,170 shares at $33.27), and earlier dates like October 15, 2025 (10,369 shares at $43.01).[[2]](https://www.marketbeat.com/instant-alerts/mineralys-therapeutics-nasdaqmlys-insider-sells-20516736-in-stock-2026-01-13/) Malcom has exercised stock options, such as 231,716 options at $12.92, increasing his holdings to 480,043 shares in prior transactions.[[3]](https://www.secform4.com/insider-trading/1672659.htm) His ongoing insider trading activity underscores his significant position within Mineralys Therapeutics, though detailed prior career highlights or educational background are not specified in available sources.[[6]](https://www.gurufocus.com/insider/60701/david-malcom-rodman)[[9]](https://www.nasdaq.com/market-activity/insiders/rodman-david-malcom-992942)

View full insider profile →

Trade Price

$26.61

Quantity

20,406

Total Value

$542,973.00

Shares Owned

76,140

Trade Date

Thursday, March 12, 2026

6 days ago

SEC Filing Date

Monday, March 16, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Mineralys Therapeutics, Inc.

Company Overview

No company information available
View news mentioning MLYS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4840253

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime